Is Johnson & Johnson (JNJ) overvalued or fairly valued?

MarketChacha shows Johnson & Johnson's valuation in context — a forward P/E of about 19.4, a price-to-book of about 7.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Johnson & Johnson (JNJ)?

Johnson & Johnson last traded at $248.82 (-1.7% on the day), as of 7/20/2026 — a delayed quote shown for education, not investment advice.

Johnson & Johnson

JNJ · NYSE · Healthcare · United States

$248.82-1.7%

Delayed · as reported by Yahoo Finance · as of Jul 20, 2026, 8:00 PM

Snapshot

TickerJNJ

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUnited States

Employees138,200

HeadquartersNew Brunswick, United States

Market cap$599.0B

P/B7.4

Volume8.11M

Websitewww.jnj.com

Filings tracked0

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.0%
Institutions76.9%
Public & other23.1%

5,708 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.86%
Vanguard Capital Management LLC6.51%
State Street Corporation5.54%
Vanguard Portfolio Management LLC2.64%
JPMORGAN CHASE & CO2.62%
Geode Capital Management, LLC2.46%
Morgan Stanley1.86%
State Farm Mutual Automobile Insurance Co1.31%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $26.5B · EPS 3.01

Est. earnings growth +22.4%

Next fiscal year

Rev $108.4B · EPS 12.83

Est. earnings growth +10.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$162.7852-wk range$269.43

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about JNJ

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.